Nomura Holdings
AVBP icon

Nomura Holdings’s ArriVent BioPharma AVBP Stock Holding History

Nomura Holdings’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.37M Sell
154,617
-87,433
-36% -$2.58M 0.01% 768
2026
Q1 		$5.58M Buy
+242,050
New +$5.47M 0.01% 608

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nomura Holdings's AVBP Position: Q2 2026 in Review

Nomura Holdings reduced its ArriVent BioPharma (AVBP) stake by 36% in Q2 2026, selling an estimated $2.58M and leaving 154,617 shares worth $5.37M. The position accounts for 0.01% of the portfolio, ranked #768.

Nomura Holdings first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.58M in Q1 2026. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Nomura Holdings held 154,617 shares of ArriVent BioPharma worth $5.37M as of Q2 2026.
  • Nomura Holdings sold 87,433 ArriVent BioPharma shares in Q2 2026, an estimated $2.58M.
  • ArriVent BioPharma made up 0.01% of Nomura Holdings's portfolio in Q2 2026, its #768 holding.
  • Nomura Holdings first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • Nomura Holdings's ArriVent BioPharma position peaked at $5.58M in Q1 2026.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.